The blockade of immune checkpoints in cancer immunotherapy
By D. Pardoll. Nature Reviews. Cancer, 2012
12,881 citations recorded by the source corpus.
Among the most promising approaches to activating therapeutic antitumour immunity is the blockade of immune checkpoints. Immune checkpoints refer to a plethora of inhibitory pathways hardwired into the immune system that are crucial for maintaining self-tolerance and modulating the duration and amplitude of physiological immune responses in peripheral tissues in order to minimize collateral tissue damage. It is now clear that tumours co-opt certain immune-checkpoint pathways as a major mechanism of immune resistance, particularly against T cells that are specific for tumour antigens. Because many of the immune checkpoints are initiated by ligand–receptor interactions, they can be readily blocked by antibodies or modulated by recombinant forms of ligands or receptors. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) antibodies were the first of this class of immunotherapeutics to achieve US Food and Drug Administration (FDA) approval. Preliminary clinical findings with blockers of additional immune-checkpoint proteins, such as programmed cell death protein 1 (PD1), indicate broad and diverse opportunities to enhance antitumour immunity with the potential to produce durable clinical responses.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/fe2b41219ee02f382f46b0bd7b300a820ff09feb
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Oncology
- J. Wolchok
- Lieping Chen
- D. Pardoll
- Antoni Ribas
- James P. Allison
- A. Mantovani
- W. Zou
- Padmanee Sharma
Citations in the corpus
- Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11 (2019, background): “CD8+ T-cell tumor infiltration and IFNγ signaling pathway activation are key features of effective immunotherapy in patients with cancer (1, 37, 38).”
- Autosomal-dominant immune dysregulation syndrome in humans with CTLA4 mutations (2014, neutral): “Interfering with the CD28/CTLA-4 pathway can therefore have both immune stimulatory and immune inhibitory effects 32-34 .”
- Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation (2015, background): “This phenomenon has extensively reported in other tumor types as innate immune resistance.(6,7) Parsa et al.”
- The microbiome and cancer (2018, background): “This is a vital tumour escape mechanism, is associated with checkpoint-mediated tumour progression, and consequently has been an important therapeutic target [67].”
- Language Models are Few-shot Learners for Prognostic Prediction (2023, background): “Particularly, in cancer immunotherapy (Pardoll, 2012), antibodies against programmed death-1/programmed death ligand 1 (PD-1/PD-L1) have led to US FDA approval of several PD-1/PD-L1 treatment strategies for patients with metastatic cancer.”
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma (2013, neutral): “5 22 3 (14 [3–35])”
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. (2016, neutral): “B-cell lymphoma (n = 31) 8 (26) 3 (10) 5 (16) 16 (52) 23 (7 to 44) DLBCL (n = 11) 4 (36) 2 (18) 2 (18) 3 (27) 7 (6 to 29) FL (n = 10) 4 (40) 1 (10) 3 (30) 6 (60) NR (7 to NR) Other B-cell lymphoma (n = 10) 0 0 0 7 (70) 11 (3 to 39) T-cell lymphoma (n = 23) 4 (17) 0 4 (17) 10 (43) 10 (7 to 33) MF (n ”
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (2012, neutral): “All patients All doses 49 5 10 (3-22) 6 12 (5-25) 31 (17-45)”
- Comprehensive analyses of tumor immunity: implications for cancer immunotherapy (2016, background): “Background Cancer immunotherapy has recently achieved remarkable success in treating late stage tumors [1, 2], but a substantial fraction of patients failed to respond [3, 4].”
- Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors (2013, background): “To assess whether other T cell inhibitory pathways were also induced in these tumors, we analyzed expression of CTLA-4, LAG-3 and Tim-3 (3).”